

PROTOCOLLO FIBROSARC_PH-L19TNFDOX2-03/16

“A Phase III study comparing the efficacy of the combination of doxorubicin and the tumor-targeting human antibody-cytokine fusion protein L19TNF to doxorubicin alone as first-line therapy in patients with advanced or metastatic soft tissue sarcoma”

Contatti: sandra.aliberti@ircc.it, simone.morabito@ircc.it (study coordinator), ufficio.trials@ircc.it

Istotipo: vari istotipi sarcomi dei tessuto molli

Presentazione: vari istotipi sarcomi dei tessuti molli, prima linea di terapia